Race-Specific Drug 'BiDil': Nitromed's Marketing Challenge
|
|
ICMR HOME | Case Studies Collection
To download Race-Specific Drug 'BiDil': Nitromed's Marketing Challenge case study
(Case Code: MKTG154) click on the button below, and select the case from the list of available cases:
» Marketing Case Studies
» Marketing Management Short Case Studies
» View Detailed Pricing Info » How To Order This Case » Business Case Studies
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
Chat with us
Please leave your feedback
|
Case Details: |
Price: |
Case Code |
: |
MKTG154 |
For delivery in electronic format: Rs.
500;
For delivery through courier (within India): Rs. 500 + Shipping & Handling Charges extra
ThemesMarketing; Advertising and Promotions, Marketing Ethics |
Case Length |
: |
29 Pages |
Period |
: |
2000-2006 |
Organization |
: |
NitroMed Inc. |
Pub Date |
: |
2006 |
Teaching Note |
: |
Available |
Countries
|
: |
USA |
Industry |
: |
Pharmaceutical |
Abstract:
This case is about BiDil, the first race-specific drug approved by the US Food
and Drug Administration for the treatment of heart failure in self-identified
African Americans in the US. BiDil was marketed by NitroMed Inc., a small
pharmaceutical company in the US. The decision to approve BiDil as a
race-specific drug was a controversial one. While some experts hailed this as
the first step toward personalized medicines, critics felt that marketing a
race-specific drug could promote racial stereotyping and create a misconception
that people of different races differed on a biological level. There were also
many others who felt that marketing BiDil as a race-specific drug was motivated
by commercial interests alone as NitroMed could extend the patent for BiDil.
|
|
Marketing the drug posed a tougher challenge
as despite a grassroots marketing effort, strategic partnership
with African American organizations, and various rounds of sales
force optimizations, the sales of BiDil were below expectations.
Many experts felt that NitroMed did not have the desired
marketing and financial strength to sustain a highly targeted
marketing effort in a multicultural setting. Others felt that
NitroMed was on the learning curve and that its new
direct-to-consumer (DTC) advertising effort could help change
things for the better.
Issues:
» Understand the issues and challenges faced by a US-based pharmaceutical
company in marketing a race-specific drug in a multicultural environment
» Understand the scientific, commercial, and ethical issues with regard to
personalized medicine and race-specific drugs in particular
Contents:
Keywords:
BiDil, NitroMed, Pharmaceutical Drug Patent, Heart Disease,
DTC advertising, Sales force optimization, Multicultural marketing, Personalized
medicine, Product optimization, Learning curve, Target marketing, Merck,
Race-specific drug, Marketing communication, Clinical Trial
The First 'Black-Only' Drug
- Next Page>>
|
|